{"id":45029,"date":"2022-06-13T23:01:37","date_gmt":"2022-06-13T21:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oscar-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/"},"modified":"2022-06-13T23:01:37","modified_gmt":"2022-06-13T21:01:37","slug":"Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/","title":{"rendered":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Accolade Health, Inc. (\u201cAccolade\u201d) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, announced that on June 8, 2022 the Compensation Committee of Accolade\u2019s Board of Directors approved the grant of inducement restricted stock unit awards covering 992,382 Class A shares of Accolade\u2019s common stock to 29 new non-executive employees of Accolade and its affiliates to induce them to join Accolade and its affiliates. The awards were granted under Accolade\u2019s 2022 Employment Inducement Award Plan, and generally vest quarterly over a three-year period following their grant, subject to continued employment. The awards were granted as employment inducement awards pursuant to the New York Stock Exchange rules.\n<\/p>\n

<\/a><\/p>\n

\nAbout Accolade Health<\/b>\n<\/p>\n

\nAccolade Health, Inc. is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Accolade, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Accolade has been challenging the healthcare system\u2019s status quo since our founding in 2012. The Company\u2019s member-first philosophy and innovative approach to care has earned us the trust of over one million members as of March 31, 2022. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Accolade, our full stack technology platform to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Accolade, we take this definition a step further. We improve our members\u2019 experience by building trust through deep engagement, personalized guidance, and rapid iteration.\n<\/p>\n

\nFor more information, please visit www.hiAccolade.com<\/a>.\n<\/p>\n

\n\u00a0\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIR:<\/b>
Cornelia Miller, Accolade
\n
917-397-0251
\n
cornelia@hiAccolade.com<\/a>\n<\/p>\n

\nMEDIA:<\/b>
Jackie Kahn, Accolade
\n
202-538-0128
\n
jkahn@hiAccolade.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Accolade Health, Inc. (\u201cAccolade\u201d) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, announced that on June 8, 2022 the Compensation Committee of Accolade\u2019s Board of Directors approved the grant of inducement restricted stock unit awards covering 992,382 Class A shares of Accolade\u2019s common stock to 29 new … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-45029","format-standard","category-industry"],"yoast_head":"\nAccolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Accolade Health, Inc. (\u201cAccolade\u201d) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, announced that on June 8, 2022 the Compensation Committee of Accolade\u2019s Board of Directors approved the grant of inducement restricted stock unit awards covering 992,382 Class A shares of Accolade\u2019s common stock to 29 new ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T21:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual\",\"datePublished\":\"2022-06-13T21:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/\"},\"wordCount\":326,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005795\\\/en\\\/1045973\\\/21\\\/Accolade_Logo_Blue.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/\",\"name\":\"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005795\\\/en\\\/1045973\\\/21\\\/Accolade_Logo_Blue.jpg\",\"datePublished\":\"2022-06-13T21:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005795\\\/en\\\/1045973\\\/21\\\/Accolade_Logo_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220613005795\\\/en\\\/1045973\\\/21\\\/Accolade_Logo_Blue.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/","og_locale":"en_US","og_type":"article","og_title":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Accolade Health, Inc. (\u201cAccolade\u201d) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, announced that on June 8, 2022 the Compensation Committee of Accolade\u2019s Board of Directors approved the grant of inducement restricted stock unit awards covering 992,382 Class A shares of Accolade\u2019s common stock to 29 new ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-13T21:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual","datePublished":"2022-06-13T21:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/"},"wordCount":326,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/","url":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/","name":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg","datePublished":"2022-06-13T21:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220613005795\/en\/1045973\/21\/Accolade_Logo_Blue.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/Accolade-health-inc-announces-inducement-grants-under-section-303a-08-of-the-nyse-listed-company-manual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Accolade Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45029"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45029\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}